Register here
Christian Klingbeil
Partner, Deal Advisory - Valuation
乐鱼（Leyu）体育官网 AG Wirtschaftspr眉fungsgesellschaft
+49 89 9282 1284 Christian
Klingbeil
Phone number
Current Issue:
The new edition of our newsletter on transactions in the global life sciences industry glances back at the significant deals that took place in 2024 and provides further insights on the industry鈥檚 market trends.
- M&A activity in the life sciences sector in 2024 remained slow and steady, demonstrating industry resilience as investors navigated a challenging business landscape characterized by heightened regulatory scrutiny and political uncertainties.
- Investors redirected their attention from de-risked, later-stage assets to preclinical and early-stage drugs, driven by the high capital premiums and ensuing competition associated with the former.
- Additionally, private equity investors opted to retain their portfolio companies in anticipation of better offers, a strategy similar to that adopted by small biotech firms seeking exits.
- However, improving business environment in the second half of the year 鈥� along with the imminent need of big pharma companies to bolster pipelines 鈥� set the stage for an active 2025.
- Small-mid cap firms with advanced assets that present near-term revenue potential and lower development risks are poised to become prime targets, gaining favor of both financial and strategic investors.
